U.S. Markets close in 5 hrs 49 mins
  • S&P 500

    3,373.45
    +10.45 (+0.31%)
     
  • Dow 30

    27,804.86
    +23.16 (+0.08%)
     
  • Nasdaq

    11,265.92
    +98.41 (+0.88%)
     
  • Russell 2000

    1,519.19
    +11.50 (+0.76%)
     
  • Crude Oil

    38.60
    -1.62 (-4.03%)
     
  • Gold

    1,907.30
    +11.80 (+0.62%)
     
  • Silver

    23.67
    +0.18 (+0.77%)
     
  • EUR/USD

    1.1741
    +0.0015 (+0.1292%)
     
  • 10-Yr Bond

    0.7050
    +0.0280 (+4.14%)
     
  • Vix

    26.22
    -0.15 (-0.57%)
     
  • GBP/USD

    1.2876
    -0.0045 (-0.3489%)
     
  • USD/JPY

    105.6280
    +0.1980 (+0.1878%)
     
  • BTC-USD

    10,867.92
    +71.88 (+0.67%)
     
  • CMC Crypto 200

    234.20
    +10.50 (+4.69%)
     
  • FTSE 100

    5,862.46
    -3.64 (-0.06%)
     
  • Nikkei 225

    23,185.12
    0.00 (0.00%)
     

Medpace Holdings, Inc. to Report Third Quarter 2020 Financial Results on October 26, 2020

Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced that it will report its third quarter 2020 financial results after the market close on Monday, October 26, 2020. The Company will host a conference call the following morning, Tuesday, October 27, 2020, at 9:00 a.m. ET to discuss these results.

To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 6989449.

To access the conference call via webcast, visit the "Investors" section of Medpace’s website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A supplemental slide presentation will also be available at the "Investors" section of Medpace’s website prior to the start of the call.

A recording of the call will be available from 12:00 p.m. ET on Tuesday, October 27, 2020 until 12:00 p.m. ET on Tuesday, November 10, 2020. To hear this recording, dial 855-859-2056 (domestic) or 404-537-3406 (international) using the passcode 6989449.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,400 people across 38 countries as of June 30, 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005844/en/

Contacts

Media Contact:
Julie Hopkins
Medpace Holdings, Inc.
513.579.9911 x12627
j.hopkins@medpace.com

Investor Contact:
investor@medpace.com